| 5/26/2020 | SP | New Issue: Goldman prices $2.12 million leveraged buffered basket-linked notes on 26 stocks
|
| 4/28/2020 | SP | New Issue: Goldman prices $910,000 leveraged basket-linked notes on 26 stocks
|
| 4/23/2020 | SP | New Issue: Goldman prices $9.16 million leveraged basket-linked notes on 26 stocks
|
| 3/4/2020 | SP | New Issue: Morgan Stanley sells $1.57 million contingent income autocalls on two stocks
|
| 2/24/2020 | SP | New Issue: CIBC prices $750,000 capped leveraged notes on basket of 50 stocks
|
| 5/31/2019 | SP | Goldman amends Cusip for notes tied to basket of Russell 3000 stocks
|
| 5/9/2019 | SP | New Issue: Goldman sells $1 million notes tied to basket of Russell 3000 stocks
|
| 3/14/2019 | SP | New Issue: Credit Suisse sells $1.45 million contingent coupon autocallable reverse convertibles on Alexion
|
| 3/7/2019 | SP | Credit Suisse plans contingent coupon autocallable reverse convertibles on Alexion
|
| 9/25/2018 | SP | New Issue: JPMorgan prices $900,000 contingent interest autocalls on three stocks
|
| 9/17/2018 | SP | JPMorgan plans autocallable contingent interest notes tied to stocks
|
| 8/31/2018 | SP | New Issue: Credit Suisse sells $1.29 million contingent coupon autocallable reverse convertibles on Alexion
|
| 8/22/2018 | SP | Credit Suisse plans 7.75% contingent coupon autocall reverse convertibles tied to Alexion
|
| 8/17/2018 | SP | New Issue: JPMorgan prices $1.81 million contingent buffered digital notes on three stocks
|
| 8/17/2018 | SP | New Issue: JPMorgan prices $1.86 million contingent buffered digital notes on three stocks
|
| 6/13/2018 | BK | Alexion secures amended and restated $3.61 billion credit agreement
|
| 2/28/2018 | SP | New Issue: Credit Suisse sells $526,000 16% autocallable reverse convertibles on three stocks
|
| 2/12/2018 | SP | New Issue: Credit Suisse sells $1.35 million 7.25% autocall reverse convertibles tied to Alexion
|
| 12/12/2017 | SP | New Issue: Credit Suisse sells $838,000 8% contingent rate autocall reverse converts on Alexion
|
| 8/1/2017 | SP | New Issue: UBS prices $300,000 trigger phoenix autocallable optimization securities linked to Alexion Pharmaceuticals
|
| 7/11/2017 | SP | New Issue: Credit Suisse sells $900,000 11.8% autocallable yield notes on two stocks
|
| 6/20/2017 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Alexion
|
| 6/12/2017 | SP | New Issue: UBS prices $548,700 trigger phoenix autocallable optimization securities linked to Alexion Pharmaceuticals
|
| 6/9/2017 | SP | New Issue: UBS prices $645,000 trigger phoenix autocallables linked to Alexion
|
| 6/7/2017 | SP | New Issue: UBS prices $365,000 trigger phoenix autocallables linked to Alexion
|
| 6/7/2017 | SP | New Issue: UBS prices $545,000 trigger phoenix autocallables linked to Alexion
|
| 6/7/2017 | SP | New Issue: UBS prices $466,000 trigger phoenix autocallables linked to Alexion
|
| 6/7/2017 | SP | New Issue: UBS prices $460,000 trigger phoenix autocallables linked to Alexion
|
| 6/7/2017 | SP | New Issue: UBS prices $535,000 airbag yield optimization notes linked to Alexion
|
| 6/5/2017 | SP | New Issue: UBS prices $299,952 9.41% trigger yield optimization notes linked to Alexion Pharmaceuticals
|
| 6/2/2017 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Alexion
|
| 6/2/2017 | SP | New Issue: UBS prices $200,000 trigger phoenix autocallables linked to Alexion
|
| 6/1/2017 | SP | New Issue: UBS prices $252,000 trigger phoenix autocallables linked to Alexion
|
| 5/31/2017 | SP | New Issue: UBS prices $685,000 trigger phoenix autocallables linked to Alexion
|
| 4/26/2017 | SP | New Issue: UBS prices $155,000 trigger phoenix autocallables linked to Alexion Pharmaceuticals
|
| 4/26/2017 | SP | New Issue: UBS prices $245,000 trigger phoenix autocallables linked to Alexion Pharmaceuticals
|
| 4/26/2017 | SP | New Issue: UBS prices $343,000 trigger phoenix autocallables linked to Alexion Pharmaceuticals
|
| 4/26/2017 | SP | New Issue: UBS prices $500,000 trigger phoenix autocallables linked to Alexion Pharmaceuticals
|
| 4/26/2017 | SP | New Issue: UBS prices $375,000 trigger phoenix autocallables linked to Alexion Pharmaceuticals
|
| 11/22/2016 | SP | New Issue: Morgan Stanley prices $6.24 million trigger participation notes linked to 45 stocks
|
| 12/8/2015 | SP | New Issue: Credit Suisse prices $308,000 autocallable reverse convertibles tied to Alexion
|
| 11/20/2015 | SP | Credit Suisse plans autocallable reverse convertibles linked to Alexion
|
| 8/20/2015 | SP | New Issue: Credit Suisse prices $431,000 8% autocallable reverse convertibles linked to Alexion
|
| 8/18/2015 | SP | New Issue: RBC prices $3.07 million 7.25% airbag autocallables linked to Alexion
|
| 8/11/2015 | SP | RBC plans to price 6%-7.25% airbag autocallables linked to Alexion
|
| 8/6/2015 | SP | Credit Suisse plans 7.5%-9.5% autocall reverse convertibles on Alexion
|
| 7/8/2015 | SP | New Issue: Credit Suisse prices $667,000 9% autocallable reverse convertibles tied to Alexion
|
| 7/2/2015 | SP | New Issue: Barclays prices $6.48 million 8% airbag autocallable notes on Alexion
|
| 6/25/2015 | SP | Credit Suisse plans 8%-10% autocallable reverse convertibles on Alexion
|
| 6/24/2015 | SP | Barclays to price 6%-8% airbag autocallables linked to Alexion
|
| 6/23/2015 | BK | Alexion Pharmaceuticals closes upsized $4 billion credit agreement
|
| 6/2/2015 | SP | New Issue: Barclays prices $3.75 million autocallable notes linked to three stocks
|
| 5/26/2015 | BK | Alexion discloses pricing on $3.5 billion secured credit facility
|
| 5/12/2015 | SP | New Issue: RBC sells $2.42 million trigger phoenix autocallables linked to Alexion
|
| 5/7/2015 | BK | Alexion discloses tranching on $3.5 billion secured credit facility
|
| 5/6/2015 | SP | RBC plans to price trigger phoenix autocallables linked to Alexion
|
| 5/6/2015 | BK | Alexion secures $3.5 billion bank financing to buy Synageva BioPharma
|
| 3/25/2015 | SP | New Issue: UBS prices $5.9 million 7.5% airbag autocallables linked to Alexion Pharmaceuticals
|
| 3/18/2015 | SP | UBS to price 6.15%-8.15% airbag autocallables linked to Alexion
|
| 3/13/2015 | SP | New Issue: Credit Suisse sells $305,000 8.5% autocallable reverse convertibles tied to Alexion
|
| 3/3/2015 | SP | Credit Suisse plans 8%-10% autocallable reverse convertibles on Alexion
|
| 1/26/2015 | SP | New Issue: RBC prices $1.51 million contingent income autocallables on Alexion Pharmaceuticals
|
| 1/21/2015 | SP | New Issue: Barclays prices $1.6 million 8.2% airbag autocallables tied to Alexion
|
| 1/16/2015 | SP | RBC plans contingent income autocallables on Alexion Pharmaceuticals
|
| 1/13/2015 | SP | Barclays plans 6.05%-8.05% airbag yield autocallables tied to Alexion
|
| 12/29/2014 | SP | New Issue: Credit Suisse prices $1.96 million 8.5% autocallable reverse convertibles on Alexion
|
| 12/3/2014 | SP | Credit Suisse plans 8%-10% autocallable reverse convertibles on Alexion
|
| 11/17/2014 | SP | New Issue: Credit Suisse prices $957,000 of 8% autocallable reverse convertibles on Alexion
|
| 11/5/2014 | SP | Credit Suisse plans autocallable reverse convertibles tied to Alexion
|
| 10/31/2014 | SP | New Issue: JPMorgan prices $233,000 contingent absolute return autocallables linked to Alexion
|
| 10/27/2014 | SP | JPMorgan plans contingent absolute return notes linked to Alexion
|
| 10/21/2014 | SP | New Issue: Barclays prices $913,900 contingent income autocallables linked to Alexion
|
| 10/21/2014 | SP | New Issue: RBC prices $936,000 9.3% airbag autocallable notes linked to Alexion
|
| 10/14/2014 | SP | RBC to price 6.2%-8.2% airbag autocallables linked to Alexion
|
| 10/14/2014 | SP | Barclays plans contingent income autocallable notes linked to Alexion
|
| 9/22/2014 | SP | RBC to price 8.3% reverse convertibles linked to Alexion Pharmaceuticals
|
| 9/17/2014 | SP | New Issue: RBC prices $85,000 10.4% reverse convertibles linked to Alexion Pharmaceuticals
|
| 9/17/2014 | SP | New Issue: RBC prices $331,000 9% reverse convertibles linked to Alexion Pharmaceuticals
|
| 9/12/2014 | SP | RBC to price 9.4% reverse convertibles linked to Alexion Pharmaceuticals
|
| 9/11/2014 | SP | RBC to price 9% reverse convertibles linked to Alexion Pharmaceuticals
|
| 9/4/2014 | SP | New Issue: Credit Suisse sells $1.25 million 9% autocallable reverse convertibles tied to Alexion
|
| 8/21/2014 | SP | RBC plans to price 9.5% reverse convertibles linked to Alexion
|
| 8/18/2014 | SP | Credit Suisse plans 9% autocallable reverse convertibles on Alexion
|
| 7/15/2014 | SP | New Issue: HSBC prices $3.61 million contingent income autocallable notes linked to Alexion
|
| 7/15/2014 | SP | New Issue: RBC prices $1.88 million 8.5% airbag autocallable yield notes linked to Alexion
|
| 7/9/2014 | SP | RBC to price 6.6%-8.6% airbag autocallables linked to Alexion
|
| 7/7/2014 | SP | HSBC to price contingent income autocallables linked to Alexion
|
| 6/30/2014 | SP | New Issue: RBC prices $195,000 11.6% reverse convertibles linked to Alexion Pharmaceuticals
|
| 6/26/2014 | SP | New Issue: Credit Suisse prices $402,000 autocallable reverse convertibles linked to Alexion
|
| 6/18/2014 | SP | RBC to price 11.6% reverse convertibles linked to Alexion Pharmaceuticals
|
| 6/5/2014 | SP | Credit Suisse plans 8.5% autocallable reverse convertibles on Alexion
|
| 5/16/2014 | SP | New Issue: RBC prices $90,000 11.5% reverse convertibles linked to Alexion Pharmaceuticals
|
| 5/13/2014 | SP | New Issue: UBS prices $382,000 airbag yield optimization notes linked to Alexion
|
| 5/9/2014 | SP | New Issue: Credit Suisse prices $2.32 million 10% autocallable reverse convertibles tied to Alexion
|
| 5/7/2014 | SP | UBS plans 6%-7.25% airbag yield optimization notes linked to Alexion
|
| 5/6/2014 | SP | RBC to price 11.5% reverse convertibles linked to Alexion Pharmaceuticals
|
| 4/30/2014 | SP | New Issue: RBC prices $752,000 13.25% reverse convertibles linked to Alexion Pharmaceuticals
|
| 4/23/2014 | SP | Credit Suisse plans 10% autocallable reverse convertibles on Alexion
|
| 4/21/2014 | SP | RBC to price 13.25% reverse convertibles linked to Alexion Pharmaceuticals
|
| 4/15/2014 | SP | New Issue: UBS prices $1.85 million contingent absolute return autocallables linked to Alexion
|
| 4/9/2014 | SP | UBS plans contingent absolute return autocallables linked to Alexion
|
| 4/4/2014 | SP | New Issue: JPMorgan prices $1.19 million 10% upside autocallable reverse exchangeables ono Alexion
|
| 3/26/2014 | SP | JPMorgan plans upside autocallable reverse exchangeables on Alexion
|
| 3/19/2014 | SP | New Issue: Credit Suisse prices $778,000 10% autocallable reverse convertibles linked to Alexion
|
| 3/10/2014 | SP | Credit Suisse plans 10% autocallable reverse convertibles on Alexion
|
| 1/23/2014 | SP | New Issue: Credit Suisse prices $771,000 9.5% autocallable reverse convertibles on Alexion
|
| 1/15/2014 | SP | New Issue: Deutsche prices $2.7 million contingent absolute return autocallables tied to Alexion
|
| 1/10/2014 | SP | Credit Suisse plans autocallable reverse convertibles tied to Alexion
|
| 1/3/2014 | SP | Deutsche Bank plans contingent absolute return notes linked to Alexion
|
| 7/9/2013 | SP | Barclays to price 8.9% reverse convertibles linked to Alexion Pharmaceuticals
|
| 7/2/2013 | SP | New Issue: Barclays prices $354,000 8.75% reverse convertibles linked to Alexion Pharmaceuticals
|
| 6/26/2013 | SP | Barclays to price 8.75% reverse convertibles linked to Alexion Pharmaceuticals
|
| 5/31/2013 | SP | New Issue: JPMorgan prices $593,250 contingent absolute return autocallables linked to Alexion
|
| 5/23/2013 | SP | JPMorgan plans contingent absolute return autocallables on Alexion
|
| 2/26/2013 | SP | New Issue: Deutsche prices $1.35 million contingent absolute return autocallables linked to Alexion
|
| 2/7/2012 | BK | Market Commentary: AMC B-1, B-2 move around as new B-3 launches; Rocket breaks; Microsemi rises on paydown
|
| 1/5/2012 | BK | Alexion launches $400 million credit facility at Libor plus 137.5 bps
|
| 1/5/2012 | BK | Market Commentary: Nielsen up on refi; Butler Schein, MetroPCS gain; Phoenix tweaks deal; Cardone postponed
|
| 12/30/2011 | BK | Alexion to get $300 million of bank debt for Enobia purchase
|
| 3/10/2011 | BK | Alexion amends credit facility, increasing revolver to $100 million
|
| 7/24/2009 | SS | Market Commentary: Bristol-Meyers predicted to continue deal pace; proxy firm sides with Foundation Coal buyout
|
| 7/23/2009 | SS | Market Commentary: Bristol-Myers' buy narrows drug field; Noven tender opens; TransAlta offer considered risky
|
| 5/29/2009 | CV | Alexion issues stock for $36.26 million total 1.375% convertibles
|
| 4/17/2009 | CV | Alexion issues stock for $4.31 million 1.375% convertibles held by CCS
|
| 4/9/2009 | CVSS | Alexion exchanges stock for 1.375% convertibles owned by Citadel
|
| 5/9/2008 | SS | Millenco owns less than 5% of Alexion
|
| 7/27/2007 | SS | Millenco owns 6.9% of Alexion Pharmaceuticals
|
| 11/27/2006 | SS | Ford shares, preferreds skid; Nasdaq, LSE slip; biotechs lower; Raytheon drops; Ventas falls
|
| 11/15/2006 | BT | New Issue: Alexion prices $129 million of stock at $43, discounted from $43.35
|
| 11/15/2006 | BT | Market Commentary: Emergent BioSolutions sinks on debut; Alexion stock deal on deck; Trimeris zooms on restructuring
|
| 11/14/2006 | BT | Market Commentary: Acambis plunges on surprise loss of new U.S. vaccine contract bid; World Heart lower; Anadys better
|
| 11/14/2006 | BT | Alexion Pharmaceuticals plans follow-on stock offering
|
| 11/14/2006 | BT | Merrill keeps Alexion at buy
|
| 11/1/2006 | BT | Alexion third-quarter revenues dip slightly; company reports $31.9 million net loss
|
| 11/1/2006 | BT | Merrill keeps Alexion at buy
|
| 11/1/2006 | BT | Market Commentary: Alexion stock climbs following earnings; Angiotech stock gives up almost 6% on 3Q earnings
|
| 9/26/2006 | BT | Alexion seeks European approval for Soliris to treat rare blood disorder
|
| 9/21/2006 | BT | Alexion maintained at buy by Merrill
|
| 9/20/2006 | BT | Alexion's Soliris improves PNH anemia, BLA filed
|
| 8/29/2006 | BT | Market Commentary: Teva lower; Endo, Penwest up; StemCells gains 7%; Nastech higher; Hemispherx rises 11%
|
| 8/8/2006 | BT | Alexion's second-quarter and first-half revenues rise
|
| 8/8/2006 | BT | Merrill reiterates Alexion at buy
|
| 7/13/2006 | BT | Alexion purchases former Dow manufacturing site to manufacture Soliris
|
| 6/29/2006 | BT | Alexion kept at buy by Merrill
|
| 6/28/2006 | BT | Alexion's pexelizumab trial does not reduce mortality
|
| 6/16/2006 | BT | Alexion to screen for paroxysmal nocturnal hemoglobinuria in patients with bone marrow failure disorders
|
| 6/12/2006 | BT | Alexion says early results of phase 3 Soliris trial meet primary, secondary endpoints
|
| 6/12/2006 | BT | Alexion reiterated at buy by Merrill
|
| 6/6/2006 | BT | Alexion says anti-CD200 antibody may suppress tumor growth
|
| 5/15/2006 | BT | Alexion: Antibody therapy shown effective in preclinical studies for asthma
|
| 5/15/2006 | BT | Merrill reiterates Alexion at buy
|
| 5/15/2006 | BT | Market Commentary: BioMimetic goes south; Sirna off on new deal; Cambridge rockets on buyout; Threshold extends fall
|
| 4/27/2006 | BT | Merrill rates Alexion at buy
|
| 4/6/2006 | BT | Alexion initiated at buy by Merrill
|
| 3/13/2006 | BT | Alexion updates phase 3 results of Primo-CABG2 study
|
| 3/10/2006 | BT | Market Commentary: Insmed, Corautus off on deals; NPS Pharma gains, dives on FDA; CV Therapeutics higher; Kos up
|
| 2/13/2006 | BT | Alexion issued patent for eculizumab in Japan
|
| 2/8/2006 | BT | Market Commentary: Pfizer news sparks buyout buzz; Immtech falls; Alkermes up; Icos off; Alexion higher; Oscient down
|
| 2/7/2006 | BT | Market Commentary: Alexion hits new high; Vertex up on data, earnings; Genitope lifted after deal; Oscient up on new pact
|
| 2/3/2006 | BT | Alexion to continue APEX-AMI trial for myocardial infarction
|
| 1/26/2006 | BT | Alexion reports positive phase 3 results for eculizumab in patients with rare blood disorder
|
| 1/26/2006 | BT | Market Commentary: Altus rockets out of gate; Teva talk tightened; Alexion zooms; Amylin better; Cephalon gains; Nektar rises
|
| 1/13/2006 | BT | Market Commentary: Nektar up over 10% on Pfizer's move; Encysive, Alexion up big; Biopure loses 4% after follow-on
|
| 1/4/2006 | BT | Alexion completes patient treatment in phase 3 trial of eculizumab
|
| 12/16/2005 | BT | Market Commentary: Amgen, Abgenix easier; takeover talk fuels rise in Imclone, several other biotechs; Kos slide continues
|
| 12/12/2005 | BT | Alexion's eculizumab shows efficacy in treating paroxysmal nocturnal hemoglobinuria, study says
|
| 11/23/2005 | BT | Alexion's phase 3 trial of pexelizumab in heart attack after bypass fails to meet its endpoint
|
| 11/23/2005 | BT | Market Commentary: Alexion stock dumped, credit widens; Ligand gobbled up; Epix dives on FDA news, cutbacks
|
| 11/23/2005 | CV | Market Commentary: Calpine extends losses; Alexion tumbles on disappointing trial; Placer Dome eyed
|
| 11/8/2005 | BT | Alexion forms subsidiary as European headquarters, hires Patrice Coissac as president
|
| 9/2/2005 | BTCV | Alexion Pharmaceuticals files $250 million shelf
|
| 8/12/2005 | BT | Market Commentary: Electro-Optical seen pricing Tuesday; Coley, China Medical mixed; Alexion slips; Isis convertible bid up
|
| 8/12/2005 | BT | New Issue: Alexion raises $66.875 million in follow-on at $26.75, discounted from $27.32 close
|
| 1/25/2005 | CV | Alexion greenshoe exercised, raising convertibles to $150 million
|
| 1/24/2005 | CV | Market Commentary: Rite Aid launches deal for Tuesday; Tower Auto bids bounce; Brocade news apt to boost bonds
|
| 1/21/2005 | CV | Market Commentary: Fortis/Assurant settles at 102.5; Celanese ends around par; Tower Automotive bonds in a freefall
|
| 1/20/2005 | CV | New Issue: Alexion sells $125 million convertible at 1.375%, up 35%
|
| 1/20/2005 | CV | Market Commentary: Celanese seen getting upsized; Fortis/Assurant issue bid well; Alexion, Antigenics trip out of chute
|
| 1/19/2005 | CV | Alexion prices $125 million convertibles to yield 1.375%, up 35%
|
| 1/19/2005 | CV | Market Commentary: Alexion goes to 102; Antigenics sweetens terms; Charter exodus continues; auto, airline paper lower
|
| 1/18/2005 | CV | Alexion $125 million convertible talked to yield 1.125%-1.625%, up 30%-35%
|
| 1/18/2005 | CV | Market Commentary: Antigenics, Alexion deals emerge; Charter slides on CEO's exit; Computer Network gains
|
| 1/18/2005 | CV | Alexion Pharmaceuticals to retire 53/4% convertibles with $125 million note sale proceeds
|
| 6/3/2004 | CV | Market Commentary: Beazer hangs around par; Phelps Dodge dividend crushes hedgers; CV Therapeutics up on drug news
|
| 8/5/2003 | CV | Market Commentary: Further cheapening noted, but many buyers waiting in wings; new deal slate remains active
|
| 1/30/2003 | CV | Deutsche sees 9 biotech issues highly probable for distressed exchange
|
| 6/12/2002 | CV | Deutsche on biopharma: buy Inhale, Cell Therapeutics; hold Abgenix, Alexion; sell Vertex, ISIS
|
| 4/10/2002 | CV | JPMorgan recommends 9 biotech convertibles for yield, capital appreciation, relative value
|
